Kaituo Pharmaceutical-B (09939.HK) plans to issue approximately 30.4875 million shares of subscription shares at a discount of about 15.03%, raising approximately HKD 49.78 million.

Zhixin Finance APP News, Kintor Pharmaceutical Limited-B (09939.HK) announced that on November 12, 2025, the company plans to issue 30,487,500 shares of subscription shares to Hua Yuan Management Consulting (Hong Kong) Limited, a wholly-owned subsidiary of Zhongxin Suzhou Industrial Park Venture Capital Co., Ltd., at a subscription price of HK$1.64 per share. This represents a discount of approximately 15.03% compared to the closing price of HK$1.93 per share on the last trading day on the Stock Exchange of Hong Kong. The net proceeds from the subscription amount to approximately HK$49.78 million, which will be used for general working capital of the group and the Phase III clinical trial of KX-826.